An Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY2287411 Injection, in Patients With Solid Tumors Known to Express Mesothelin
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2019
At a glance
- Drugs BAY-2287411 (Primary)
- Indications Mesothelioma; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 27 Dec 2018 Planned End Date changed from 20 Dec 2022 to 20 Feb 2023.
- 26 Sep 2018 Planned number of patients changed from 42 to 228.
- 26 Sep 2018 Planned End Date changed from 1 Jan 2021 to 20 Dec 2022.